- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09:45 | SKB BIO-B (06990): VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR SKB103 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 2 | HKEx | ||
| 04:31 | Kelun-Biotech Announced 2025 Annual Results: Multiple Products Successfully Launched With Tiered Pipeline Ready For Take-off | 240 | PR Newswire | Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximat ely RMB1478.78 mill ion, representing a year-on-year increase.
... ► Artikel lesen | |
| Mo | SKB BIO-B (06990): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| Mi | SKB BIO-B (06990): VOLUNTARY ANNOUNCEMENT STUDY RESULTS FROM CORE PRODUCT SACITUZUMAB TIRUMOTECAN (SAC-TMT) AT 2026 ELCC | 1 | HKEx | ||
| 11.03. | SKB BIO-B (06990): NOTICE OF BOARD MEETING | - | HKEx | ||
| 10.03. | SKB BIO-B (06990): CONTINUING CONNECTED TRANSACTION AUXILIARY PROMOTIONAL SERVICES FRAMEWORK AGREEMENT | - | HKEx | ||
| 09.03. | SKB BIO-B (06990): VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR SKB575 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 1 | HKEx | ||
| SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 06.02. | SKB BIO-B (06990): VOLUNTARY ANNOUNCEMENT CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (SAC-TMT) APPROVED FOR MARKETING FOR FOURTH INDICATION BY THE ... | 2 | HKEx | ||
| 23.01. | SKB BIO-B (06990): SUPPLEMENTARY ANNOUNCEMENT CONTINUING CONNECTED TRANSACTION 2026 R&D-RELATED GOODS FRAMEWORK AGREEMENT | 1 | HKEx | ||
| 16.01. | SKB BIO-B (06990): CONTINUING CONNECTED TRANSACTION 2026 R&D-RELATED GOODS FRAMEWORK AGREEMENT | - | HKEx | ||
| 07.01. | SKB BIO-B (06990): TERMINATION OF DISCLOSEABLE TRANSACTION IN RELATION TO SUBSCRIPTION FOR WEALTH MANAGEMENT PRODUCT | - | HKEx | ||
| 06.01. | SKB BIO-B (06990): DISCLOSEABLE TRANSACTION SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
| 05.01. | Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC | 96 | PR Newswire | CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that... ► Artikel lesen | |
| 05.01. | SKB BIO-B (06990): VOLUNTARY ANNOUNCEMENT CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (SAC-TMT) IN COMBINATION WITH IMMUNOTHERAPY PEMBROLIZUMAB GRANTED ... | 1 | HKEx | ||
| 31.12.25 | SKB BIO-B (06990): CONTINUING CONNECTED TRANSACTION 2026 SALES AND DISTRIBUTION FRAMEWORK AGREEMENT | 2 | HKEx | ||
| 31.12.25 | SKB BIO-B (06990): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 31, 2025 | - | HKEx | ||
| 16.12.25 | SKB BIO-B (06990): VOLUNTARY ANNOUNCEMENT SETTLEMENT OF DISPUTES | - | HKEx | ||
| 15.12.25 | SKB BIO-B (06990): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON DECEMBER 31, 2025 | - | HKEx | ||
| 15.12.25 | SKB BIO-B (06990): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 15.12.25 | SKB BIO-B (06990): CONTINUING CONNECTED TRANSACTIONS; PROPOSED ADOPTION OF THE 2025 SHARE INCENTIVE SCHEME; AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 4,750 | 0,00 % | What's Going On With bioAffinity Stock Thursday? | ||
| APOGEE THERAPEUTICS | 79,16 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CG ONCOLOGY | 64,92 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,750 | 0,00 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen | |
| QIAGEN | 34,400 | +0,45 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ERASCA | 14,310 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| ARCELLX | 114,61 | 0,00 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,570 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| PRAXIS PRECISION MEDICINES | 293,87 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| TYRA BIOSCIENCES | 36,500 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,400 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| BIONTECH | 76,00 | -1,43 % | Nach eigenem Bekunden konzentriert sich BioNTech bei der Suche nach einem neuen CEO vor allem auf die USA | Der kürzlich angekündigte Rücktritt der BioNTech Gründer Ugur Sahin und Özlem Türeci sorgte für einen Schock an der Börse und auch anderswo für Unsicherheit. Die Stadt Mainz scheint bereits darum zu... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 49,080 | +1,15 % | Citizens reiterates Structure Therapeutics stock rating on weight loss data | ||
| VALNEVA | 2,964 | -34,42 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| ALUMIS | 23,370 | 0,00 % | Alumis Inc.: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements | - Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis... ► Artikel lesen |
Das Unternehmen SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.